Video interview with BioViva’s Liz Parrish

BioViva and Integrated Health Systems: How many patients in trials? Where are they located? What pipeline stage?

As we’ve covered in the past, BioViva’s Liz Parrish has ambitions to progress the Longevity field, and as with many early-stage companies, things move fast as financial, regulatory and market dynamics change.

Longevity.Technology: We weren’t completely clear on BioViva’s strategy so we thought a video interview would be a great way to share the insights; so from telomere testing kits for pets (as a roadmap to human therapies) through to going into clinical trials with human data:

As Liz told us earlier this year: “… if it’s agreed between the medical doctor and the patient to take an experimental therapeutic they can do that. And that should be the right anywhere in the world – everyone should have the agency and autonomy to do that. Unfortunately, they don’t.”


Phil Newman
Editor-in-Chief Phil has over 25 years of C-level management, marketing and business development expertise in Europe and North America. His creative background has helped him shape unconventional strategies for commercial growth - garnering both awards and investor ROI.

Phil has wide experience of technology transfer and the commercialisation of innovations from both private and institutional sources and this led to his interest in Longevity and the founding of Longevity.Technology.

Latest articles

VC enters Longevity market with K4Connect deal

We talk with VC investor Forte Ventures about its first foray into AgeTech, COVID-19 and the Longevity investment opportunity. Longevity agetech company K4Connect has announced...

Challenging the one drug/one disease model

A new paper supports the targeting of aging processes, rather than just one disease, to improve Longevity outcomes. Multimorbidity is a challenge for Longevity; defined...

Robotics and AI combine for new therapeutics discovery

Insilico Medicine and Arctoris announce robotics/AI partnership to focus on COVID-19 inhibitors that could have wide-reaching benefits for Longevity. Two companies have joined forces in...

The results are in: sharing our Longevity investment survey

There is rapidly-increasing activity in both the research and the investment communities that focus on Longevity; this survey gets into the details. The global Longevity...